Vicore Pharma Holding AB (publ) (VCRE)
| Market Cap | 327.24M +15.0% |
| Revenue (ttm) | 370,609 -41.2% |
| Net Income | -49.87M |
| EPS | -0.20 |
| Shares Out | 281.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 345 |
| Open | 12.08 |
| Previous Close | 12.23 |
| Day's Range | 11.05 - 12.34 |
| 52-Week Range | 10.50 - 17.80 |
| Beta | 0.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About VCRE
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III cl... [Read more]
Financial Performance
In 2025, Vicore Pharma Holding AB's revenue was 3.82 million, a decrease of -96.51% compared to the previous year's 109.35 million. Losses were -477.47 million, 183.1% more than in 2024.
Financial numbers in SEK Financial StatementsNews
Vicore Pharma to Participate in the Leerink Therapeutics Forum
STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of d...
Vicore Pharma Holding AB Transcript: Status update
Enrollment in the phase IIb ASPIRE trial for buloxibutid in IPF was completed ahead of schedule, with a futility analysis expected in Q4 and top-line data mid-next year. Current IPF therapies have significant tolerability issues, and buloxibutid aims to address unmet needs with a novel mechanism and promising early data.
Vicore Pharma Holding AB Press release: Status update
Vicore Pharma Holding AB issued a press release on June 8, 2026, disclosing material business information to investors.
Vicore Pharma Holding AB Slides: Status update
Vicore Pharma Holding AB has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Vicore Pharma Holding AB Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a novel oral therapy for IPF, targeting epithelial injury and vascular dysfunction, with promising phase IIa results and a large phase IIb trial recently completing enrollment. The therapy is positioned for strong tolerability and commercial potential, with key data readouts and regulatory milestones expected over the next year.
Vicore Pharma Holding AB Slides: Company presentation
Vicore Pharma Holding AB has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Vicore Pharma Holding AB Quarterly report: Q1 2026
Vicore Pharma Holding AB has published its Q1 2026 quarterly earnings report on May 6, 2026.
Vicore Pharma Holding AB Slides: Company presentation
Vicore Pharma Holding AB has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Vicore Pharma Holding AB Transcript: Leerink Global Healthcare Conference 2026
A novel AT2 receptor agonist is advancing in a large phase II-B IPF trial, with strong early efficacy and safety signals, and enrollment completion expected in H1 2024. The therapy's unique mechanism and tolerability profile position it for frontline or combination use, with future expansion into other fibrotic diseases considered.
Vicore Pharma Holding AB at TD Cowen Healthcare Conference Transcript
Vicore Pharma Holding AB at TD Cowen Healthcare Conference Transcript
Vicore Pharma Holding AB Transcript: TD Cowen 46th Annual Health Care Conference
Buloxibutid, an oral AT2 receptor agonist, demonstrated unprecedented lung function improvement in IPF patients, with strong safety and tolerability in Phase 2a. The ongoing Phase 2b trial aims to confirm efficacy and broaden use as a frontline therapy, with enrollment completion expected in H1 2024.
Vicore Pharma Holding AB Annual report: Q4 2025
Vicore Pharma Holding AB has published its Q4 2025 annual report on February 27, 2026.
Vicore Pharma Holding AB Quarterly report: Q4 2025
Vicore Pharma Holding AB has published its Q4 2025 quarterly earnings report on February 27, 2026.
Vicore Pharma Holding AB Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Buloxibutid, an oral AT2 receptor agonist, is advancing in late-stage IPF development, showing promising efficacy and tolerability in phase II-A trials. A phase IIb study is underway, with top-line data expected in mid-2027 and sufficient cash runway through mid-2028.
Vicore Pharma Holding AB Transcript: 44th Annual J.P. Morgan Healthcare Conference
A novel oral therapy targeting the AT2 receptor for IPF showed improved lung function and strong tolerability in a nine-month phase II-A study, with a large phase II-B/III trial underway. The approach addresses key disease mechanisms and aims to outperform current therapies.
Vicore Pharma Holding AB Slides: Company presentation
Vicore Pharma Holding AB has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
Vicore Pharma Holding AB Transcript: Jefferies London Healthcare Conference 2025
Buloxibutid, a first-in-class therapy for IPF, demonstrated promising efficacy and safety in phase IIa trials, with over 200 mL improvement in lung function and a favorable side effect profile. The ongoing phase IIb trial, now expanded to 360 patients, aims to confirm these results globally.
Vicore Pharma Holding AB Slides: FY 2025
Vicore Pharma Holding AB has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 18, 2025.
Vicore Pharma Holding AB Transcript: Stifel 2025 Healthcare Conference
IPF remains a fatal disease with limited, incremental therapies and high unmet need. Buloxibutid, targeting the AT2 receptor, has shown promising lung function improvement and safety in early trials, with a robust phase II-B study underway and strong financial and partnership support.
Vicore Pharma Holding AB Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The company is advancing a novel therapy for IPF targeting the angiotensin II type II receptor, showing promising phase IIA results with improved lung function. A large phase IIB trial is underway, with top-line data expected in 2027, and the company is well-funded to reach key milestones.
Vicore Pharma Holding AB Quarterly report: Q3 2025
Vicore Pharma Holding AB has published its Q3 2025 quarterly earnings report on November 5, 2025.
Vicore Pharma Holding AB Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
The company is advancing a novel AT2 receptor agonist for IPF, aiming to address both fibrosis and vascular dysfunction. Phase IIA data showed unprecedented lung function improvement, and a large global phase IIB trial is underway with results expected in 2027. Financially secure, the company is exploring flexible commercialization strategies.
Vicore Pharma Holding AB Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
A novel AT2 receptor agonist for IPF demonstrated strong preclinical and phase II-A results, with a 200 mL lung function improvement over 36 weeks and a favorable safety profile. A 52-week phase II-B trial is underway, aiming for broad adoption and future indication expansion.
Vicore Pharma Holding AB Transcript: Cantor Global Healthcare Conference 2025
A novel IPF therapy targeting epithelial repair, fibrosis, and vascular dysfunction showed strong lung function improvement in a phase IIa study, with a robust phase IIb trial underway. The company is well-funded, exploring U.S. listing, and has strategic partnerships in place.
Vicore Pharma Holding AB Quarterly report: Q2 2025
Vicore Pharma Holding AB has published its Q2 2025 quarterly earnings report on August 22, 2025.